HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Picks Outsider With Broad Experience To Lead Consumer Group

This article was originally published in The Rose Sheet

Executive Summary

Bayer CropScience CEO Sandra Peterson will join Johnson & Johnson Dec. 1 as group worldwide chairman with oversight of consumer companies, IT and global supply chain. Worldwide Consumer Group Chairman Jesse Wu will report to Peterson, who also takes a seat on J&J’s executive committee.

You may also be interested in...



J&J’s Path Forward – An Interview With Alex Gorsky

In a conversation shortly before taking the helm at Johnson & Johnson, CEO Gorsky discusses deal strategies, emerging markets, his experience overseeing both the device and pharma businesses and the value of J&J’s consumer health product portfolio.

Can Avon CEO McCoy Rise To “Superhuman” Task?

New CEO Sheri McCoy comes to Avon from Johnson & Johnson with a strong background in consumer products and a “significant turn-around track record,” according to Avon. However, “there is no cape flowing behind her,” notes Morningstar analyst Lauren DeSanto, speculating that Avon’s problems may require superhuman powers.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel